PFE · Pfizer, Inc.
Healthcare NYQ United States pfizer.com ↗
BEARISH BUY
Val Gro Qua Mom Sta Cap P/SN/A P/E Fwd P/E8.88 PEG2.91 52W –  RSI Target$28.75 (+14.3%) Beta0.31 Div6.81%
Loading chart…
RSI (14)
Pattern Overlays
Loading patterns…
Drug Manufacturers - General New York, United States 75,000 employees
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
52-Week Range
52W Low 52W High
Position in Range
RSI (14)
0 · Oversold RSI 59 Overbought · 100
Signal Neutral
EMA Price Levels
Volume Analysis
Momentum Dashboard
Trend Strength
Detected Patterns
0Bullish
3Bearish
0Neutral
▼ Double Top — Two peaks ~$27.37 — bearish reversal confirmed
▼ Bear Flag — Breakdown after -8% pole — bearish continuation
▼ Double Top — Two peaks ~$26.50 — bearish reversal confirmed

View overlays on the price chart via Chart tab → Pattern Overlays.

Next Earnings Aug 04, 2026
Beat Rate 100%
Consensus BUY
Analyst Upside +14.3%
EPS — History & Forecast
Estimate Beat Miss Forecast
Loading…
Revenue — History & Forecast
Revenue Forecast
Loading…
EPS Beat Rate
100% 8/8 quarters
Wall Street Consensus
BUY
10
16
2
BuyHoldSell
Price Target Range
$28.75 +14.3% upside
Low $24 High $35
Consensus Current price
Wall Street Analyst Ratings
FirmRatingChangeActionDate
BMO Capital Outperform ↔ Maintain 2026-07-13
Guggenheim Buy ↔ Maintain 2026-07-13
B of A Securities Neutral ↔ Maintain 2026-07-10
JP Morgan Neutral ↔ Maintain 2026-07-08
Cantor Fitzgerald Neutral ↔ Reiterate 2026-07-06
HSBC Hold Buy Hold ▼ Downgrade 2026-07-06
RBC Capital Sector Perform Underperform Sector Perform ▲ Upgrade 2026-06-10
Citigroup Neutral ↔ Maintain 2026-04-29
CICC Outperform ● Initiate 2026-04-16
UBS Neutral ↔ Maintain 2026-04-13
Morgan Stanley Equal-Weight ↔ Maintain 2026-04-10
Argus Research Buy Hold Buy ▲ Upgrade 2026-03-02
Barclays Underweight ● Initiate 2026-02-20
Freedom Broker Buy ↔ Maintain 2026-02-09
BMO Capital 2026-07-13
Outperform ↔ Maintain
Guggenheim 2026-07-13
Buy ↔ Maintain
B of A Securities 2026-07-10
Neutral ↔ Maintain
JP Morgan 2026-07-08
Neutral ↔ Maintain
Cantor Fitzgerald 2026-07-06
Neutral ↔ Reiterate
HSBC 2026-07-06
Hold (from Buy) ▼ Downgrade
RBC Capital 2026-06-10
Sector Perform (from Underperform) ▲ Upgrade
Citigroup 2026-04-29
Neutral ↔ Maintain
CICC 2026-04-16
Outperform ● Initiate
UBS 2026-04-13
Neutral ↔ Maintain
Morgan Stanley 2026-04-10
Equal-Weight ↔ Maintain
Argus Research 2026-03-02
Buy (from Hold) ▲ Upgrade
Barclays 2026-02-20
Underweight ● Initiate
Freedom Broker 2026-02-09
Buy ↔ Maintain
Profitability
Gross Margin 74.80%TTM
Op. Margin 31.62%TTM
ROE 8.31%TTM
Rev. Growth 5.40%YoY
Free Cash Flow 12.38BTTM
FCF Yield TTM
Balance Sheet
Debt / Equity 71.60MRQ
Current Ratio 1.25MRQ
Cash 13.08BMRQ
Total Debt 64.73BMRQ
Net Debt MRQ
Income
Div. Yield 6.81%TTM
Annual Rate 1.72Fwd
Payout Ratio 131.30%TTM
Dividend History
Payout Ratio (TTM): 131.30%
DateAmount / ShareYield at Payment
2026-07-24 $0.4300 1.75%
2026-05-08 $0.4300 1.70%
2026-01-23 $0.4300 1.73%
2025-11-07 $0.4300 1.85%
2025-07-25 $0.4300 1.86%
2025-05-09 $0.4300 2.10%
2025-01-24 $0.4300 1.83%
2024-11-08 $0.4200 1.77%
2024-07-26 $0.4200 1.56%
2024-05-09 $0.4200 1.73%
2024-01-25 $0.4200 1.80%
2023-11-09 $0.4100 1.65%
2023-07-27 $0.4100 1.37%
2023-05-11 $0.4100 1.34%
2023-01-26 $0.4100 1.15%
2022-11-03 $0.4000 1.07%
2022-07-28 $0.4000 0.99%
2022-05-12 $0.4000 1.01%
2022-01-27 $0.4000 0.96%
2021-11-04 $0.3900 1.15%
2021-07-29 $0.3900 1.19%
2021-05-06 $0.3900 1.31%
2021-01-28 $0.3900 1.44%
2020-11-05 $0.3605 1.40%
2020-07-30 $0.3605 1.33%
2020-05-07 $0.3605 1.41%
2020-01-30 $0.3605 1.42%
2019-11-07 $0.3416 1.36%
2019-08-01 $0.3416 1.33%
2019-05-09 $0.3416 1.26%
2019-01-31 $0.3416 1.22%
2018-11-08 $0.3226 1.12%
2018-08-02 $0.3226 1.25%
2018-05-10 $0.3226 1.43%
2018-02-01 $0.3226 1.37%
2017-11-09 $0.3036 1.36%
2017-08-02 $0.3036 1.47%
2017-05-10 $0.3036 1.48%
2017-02-01 $0.3036 1.56%
2016-11-08 $0.2846 1.56%
How PFE Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
QuarterRevenueRev YoYGross Profit Op. IncomeNet IncomeNet YoY Gross %Op %Net %
Full Key Statistics
Valuation
Market CapN/A
Enterprise Value195.29B
Trailing P/E19.20
Forward P/E8.88
PEG Ratio (5yr)2.91
Price/Sales (ttm)N/A
Price/Book (mrq)1.59
EV/Revenue3.08
EV/EBITDA7.67
Share Statistics
Avg Vol (3m)41.16M
Shares OutstandingN/A
Float5.69B
% Held by Insiders0.10%
% Held by Institutions69.56%
Short Ratio3.21
Short % of Float2.87%
Profitability
Gross Margin74.80%
Operating Margin (ttm)31.62%
Profit Margin11.83%
Return on Assets (ttm)5.69%
Return on Equity (ttm)8.31%
Income Statement
Revenue (ttm)63.32B
Revenue Growth (yoy)5.40%
Gross Profit (ttm)47.36B
EBITDA25.46B
Net Income (ttm)7.48B
Diluted EPS (ttm)1.31
EPS Growth (yoy)-10.10%
Balance Sheet
Total Cash (mrq)13.08B
Total Debt (mrq)64.73B
Debt / Equity (mrq)71.60
Current Ratio (mrq)1.25
Book Value / Share15.81
Operating CF (ttm)11.98B
Free Cash Flow (ttm)12.38B
Trading & Dividends
Beta (5Y)0.31
50-Day MA25.11
200-Day MA25.83
Fwd Dividend Yield681.00%
Payout Ratio131.30%
Ownership Breakdown
Institutional 69.56% Insider 0.10% Public 30.3%
Short Interest 2.87% of float
Low
Institutional 13F Holdings

Famous investors who disclosed a position in PFE in their latest SEC 13F filing.

Loading…
Insider Transactions
DateInsiderRoleTransactionSharesValue
2026-06-09 DAMICO JENNIFER B. Officer Sale at price 25.70 per share. 2,000 $51,400
2026-03-03 DAMICO JENNIFER B. Officer Stock Award(Grant) at price 0.00 per share. 21,719
2026-02-25 BOSHOFF CHRISTOFFEL Officer Stock Award(Grant) at price 0.00 per share. 13,383
2026-02-25 DAMICO JENNIFER B. Officer Conversion of Exercise of derivative security at price 33.82 per share. 17,558 $593,812
2026-02-25 SAHNI PAYAL Officer Conversion of Exercise of derivative security at price 33.82 per share. 56,888 $1,923,952
2026-02-25 MCDERMOTT MICHAEL Officer Conversion of Exercise of derivative security at price 33.82 per share. 37,925 $1,282,624
2026-02-25 BOURLA ALBERT Chief Executive Officer Conversion of Exercise of derivative security at price 33.82 per share. 491,626 $16,626,791
2026-02-25 LANKLER DOUGLAS M Officer Conversion of Exercise of derivative security at price 33.82 per share. 122,907 $4,156,715
2026-02-25 FONSECA LIDIA PH.D. Officer Conversion of Exercise of derivative security at price 33.82 per share. 56,888 $1,923,952
2025-03-04 DAMICO JENNIFER B. Officer Stock Award(Grant) at price 0.00 per share. 5,583
2025-03-04 DAMICO JENNIFER B. Officer Sale at price 25.93 per share. 2,500 $64,825
2025-02-27 BOSHOFF CHRISTOFFEL Officer Stock Award(Grant) at price 0.00 per share. 17,450
2025-02-27 DAMICO JENNIFER B. Officer Conversion of Exercise of derivative security at price 31.31 per share. 22,416 $701,845
2025-02-27 SAHNI PAYAL Officer Conversion of Exercise of derivative security at price 31.31 per share. 19,054 $596,581
2025-02-27 MCDERMOTT MICHAEL Officer Conversion of Exercise of derivative security at price 31.31 per share. 48,419 $1,515,999
2025-02-27 BOURLA ALBERT Chief Executive Officer Conversion of Exercise of derivative security at price 31.31 per share. 582,823 $18,248,188
2025-02-27 LANKLER DOUGLAS M Officer Conversion of Exercise of derivative security at price 31.31 per share. 156,914 $4,912,977
2025-02-27 FONSECA LIDIA PH.D. Officer Conversion of Exercise of derivative security at price 31.31 per share. 72,629 $2,274,014
2025-02-27 SUSMAN SALLY Officer Conversion of Exercise of derivative security at price 31.31 per share. 85,182 $2,667,048
2025-02-26 BOSHOFF CHRISTOFFEL Officer Stock Award(Grant) at price 0.00 per share. 9,687
2025-02-21 BOSHOFF CHRISTOFFEL Officer Conversion of Exercise of derivative security at price 30.17 per share. 8,741 $263,716
2025-02-21 BOSHOFF CHRISTOFFEL Officer Conversion of Exercise of derivative security at price 30.17 per share. 8,741 $263,716
2025-02-21 DAMICO JENNIFER B. Officer Conversion of Exercise of derivative security at price 30.17 per share. 8,741 $263,716
2025-02-21 SAHNI PAYAL Officer Conversion of Exercise of derivative security at price 30.17 per share. 12,714 $383,581
2025-02-21 MCDERMOTT MICHAEL Officer Conversion of Exercise of derivative security at price 30.17 per share. 11,125 $335,641
DAMICO JENNIFER B. Officer
Sale at price 25.70 per share.
2026-06-09 2,000 sh $51,400
DAMICO JENNIFER B. Officer
Stock Award(Grant) at price 0.00 per share.
2026-03-03 21,719 sh
BOSHOFF CHRISTOFFEL Officer
Stock Award(Grant) at price 0.00 per share.
2026-02-25 13,383 sh
DAMICO JENNIFER B. Officer
Conversion of Exercise of derivative security at price 33.82 per share.
2026-02-25 17,558 sh $593,812
SAHNI PAYAL Officer
Conversion of Exercise of derivative security at price 33.82 per share.
2026-02-25 56,888 sh $1,923,952
MCDERMOTT MICHAEL Officer
Conversion of Exercise of derivative security at price 33.82 per share.
2026-02-25 37,925 sh $1,282,624
BOURLA ALBERT Chief Executive Officer
Conversion of Exercise of derivative security at price 33.82 per share.
2026-02-25 491,626 sh $16,626,791
LANKLER DOUGLAS M Officer
Conversion of Exercise of derivative security at price 33.82 per share.
2026-02-25 122,907 sh $4,156,715
FONSECA LIDIA PH.D. Officer
Conversion of Exercise of derivative security at price 33.82 per share.
2026-02-25 56,888 sh $1,923,952
DAMICO JENNIFER B. Officer
Stock Award(Grant) at price 0.00 per share.
2025-03-04 5,583 sh
DAMICO JENNIFER B. Officer
Sale at price 25.93 per share.
2025-03-04 2,500 sh $64,825
BOSHOFF CHRISTOFFEL Officer
Stock Award(Grant) at price 0.00 per share.
2025-02-27 17,450 sh
DAMICO JENNIFER B. Officer
Conversion of Exercise of derivative security at price 31.31 per share.
2025-02-27 22,416 sh $701,845
SAHNI PAYAL Officer
Conversion of Exercise of derivative security at price 31.31 per share.
2025-02-27 19,054 sh $596,581
MCDERMOTT MICHAEL Officer
Conversion of Exercise of derivative security at price 31.31 per share.
2025-02-27 48,419 sh $1,515,999
BOURLA ALBERT Chief Executive Officer
Conversion of Exercise of derivative security at price 31.31 per share.
2025-02-27 582,823 sh $18,248,188
LANKLER DOUGLAS M Officer
Conversion of Exercise of derivative security at price 31.31 per share.
2025-02-27 156,914 sh $4,912,977
FONSECA LIDIA PH.D. Officer
Conversion of Exercise of derivative security at price 31.31 per share.
2025-02-27 72,629 sh $2,274,014
SUSMAN SALLY Officer
Conversion of Exercise of derivative security at price 31.31 per share.
2025-02-27 85,182 sh $2,667,048
BOSHOFF CHRISTOFFEL Officer
Stock Award(Grant) at price 0.00 per share.
2025-02-26 9,687 sh
BOSHOFF CHRISTOFFEL Officer
Conversion of Exercise of derivative security at price 30.17 per share.
2025-02-21 8,741 sh $263,716
BOSHOFF CHRISTOFFEL Officer
Conversion of Exercise of derivative security at price 30.17 per share.
2025-02-21 8,741 sh $263,716
DAMICO JENNIFER B. Officer
Conversion of Exercise of derivative security at price 30.17 per share.
2025-02-21 8,741 sh $263,716
SAHNI PAYAL Officer
Conversion of Exercise of derivative security at price 30.17 per share.
2025-02-21 12,714 sh $383,581
MCDERMOTT MICHAEL Officer
Conversion of Exercise of derivative security at price 30.17 per share.
2025-02-21 11,125 sh $335,641